文献速递妇科生殖医学

治疗前24小时HCG增幅及第1至4天HCG变化可早期预测甲氨蝶呤治疗成功

Early prediction of the success of methotrexate treatment success by 24-hour pretreatment increment in HCG and day 1-4 change in HCG.
PubMed 文献 · Reprod Biomed Online · 2019-02-27

本研究为回顾性队列研究,纳入292例接受单次肌内注射甲氨蝶呤治疗的异位妊娠女性,比较治疗成功组与失败组的母体及妊娠特征。单次给药治疗成功率为62.7%(183/292);治疗前24小时HCG百分比增幅(校正OR 1.82,95%CI 1.26-2.63;P<0.001)与第1至4天HCG百分比变化(校正OR 1.12,95%CI 1.04-1.21;P<0.001)为治疗成功的独立决定因素。

要点

  • 单次肌内注射甲氨蝶呤治疗异位妊娠的成功率为62.7%(183/292)。
  • 治疗前24小时HCG增幅与第1至4天HCG变化均与治疗成功独立相关。
  • 预测治疗成功的较优界值为治疗前24小时HCG增幅小于17%、第1至4天HCG下降大于22%。

核心结论

  • 治疗前24小时HCG浓度小幅升高,同时第1至4天HCG浓度下降,可能预测异位妊娠药物治疗的成功。

研究设计与样本

  • 回顾性队列研究,纳入292例诊断为异位妊娠并接受单次剂量甲氨蝶呤方案治疗的女性。
  • 比较治疗成功组与治疗失败组的母体及妊娠特征。

主要发现

  • 总体队列中单次剂量甲氨蝶呤治疗成功率为62.7%(183/292)。
  • 仅有两个独立决定因素与治疗成功显著相关:治疗前24小时HCG百分比增幅(校正OR 1.82,95%CI 1.26-2.63;P<0.001)与第1至4天HCG百分比变化(校正OR 1.12,95%CI 1.04-1.21;P<0.001)。

关键数值与推荐

  • 预测治疗成功的较优界值为治疗前24小时HCG增幅小于17%。
  • 预测治疗成功的较优界值为第1天至第4天HCG浓度下降大于22%。

临床怎么用

  • 原文结论指出,治疗前24小时HCG小幅升高伴第1至4天HCG下降,可能预测异位妊娠药物治疗的成功。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Several studies have tried to identify early markers of treatment outcome after methotrexate (MTX) treatment for ectopic pregnancy, including pretreatment and day 4 human chorionic gonadotrophin (HCG) concentrations and their corresponding changes, and the increment in HCG during the initial 24 h after treatment. There have, however, been conflicting results. This study aimed to re-evaluate the role of these markers in the earlier identification of treatment success in a large cohort of women. DESIGN: This was a retrospective cohort study including women diagnosed with an ectopic pregnancy and treated with a regimen of a single dose of MTX. A comparison of maternal and gestation characteristics was made between groups in whom treatment was successful or failed. RESULTS: A total of 292 women treated with single-dose intramuscular MTX for ectopic pregnancy were included in this study. In the overall cohort, the treatment success rate with a single dose of MTX was 62.7% (183/292). Only two independent determinants were significantly associated with treatment success: the initial 24-h percentage increase in HCG (adjusted odds ratio [OR] 1.82, 95% confidence interval [CI] 1.26-2.63; P < 0.001) and the percentage change in HCG from day 1 to day 4 (adjusted OR 1.12, 95% CI 1.04-1.21; P < 0.001). The optimal cut-off points for prediction of treatment success were an increment of less than 17% in the 24 h before treatment and a decrease of more than 22% between the day 1 and day 4 HCG concentrations. CONCLUSIONS: A small increase in HCG concentration 24 h before treatment with MTX, alongside a decline in HCG concentration from day 1 to day 4, may predict the success of medical treatment for an ectopic pregnancy.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Levin G, Dior U, Shushan A, et al. Early prediction of the success of methotrexate treatment success by 24-hour pretreatment increment in HCG and day 1-4 change in HCG. Reprod Biomed Online. 2019. PMID: 31029556. doi:10.1016/j.rbmo.2019.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。